30.04.2020 • NewsElaine BurridgeSyngentaNovozymes

Syngenta and Novozymes Win Taegro Approvals

After more than seven years of collaboration, Syngenta and Novozymes are now entering the commercialization phase of their microbial-based foliar fungicide Taegro.

Syngenta and Novozymes Win Taegro Approvals
Syngenta and Novozymes Win Taegro Approvals

The companies, which entered into an exclusive global marketing and distribution agreement in October 2012, have now received the first wave of approvals in Belgium, Bulgaria, Czech Republic, France, Germany, Greece, Honduras, Italy, the Netherlands, Romania, Slovenia, Spain and the UK.

They are expecting to gain more approvals across the EU and Latin America during the next 12 months, which will enable multiple product launches in 2020.

“This collaboration matches Syngenta’s global market strength in biocontrol and dedication to bring novel technologies to market with Novozymes’ deep knowledge of sustainable, biological solutions,” said Thomas Batchelor, Novozymes’ vice president of BioAg Commercial. “As the developer and producer of Taegro, we are really excited to see another microbial technology become available to farmers to help them sustainably combat crop diseases and avoid significant yield losses.”

Taegro, which is based on the naturally occurring Bacillus subtilis bacterium, is said to have broad spectrum potential to resist fungal diseases, such as powdery mildew and botrytis, across various fruit and vegetable crops.

The fungicide’s application is expected to be expanded to a wider portfolio of broad-acre crops such as wheat, soy and corn.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.